Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE | Zendy

Mira Mousa | Zendy; Mohammed Albreiki | Zendy; Fatima Alshehhi | Zendy; Safiya AlShamsi | Zendy; Nada Al Marzouqi | Zendy; Tayba Alawadi | Zendy; Hussain Alrand | Zendy; Habiba Alsafar | Zendy; Asma Fikri | Zendy

Open Access

Similar effectiveness of the inactivated vaccine BBIBP-CorV (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related hospitalizations during the Delta outbreak in the UAE

Author(s) -

Mira Mousa,

Mohammed Albreiki,

Fatima Alshehhi,

Safiya AlShamsi,

Nada Al Marzouqi,

Tayba Alawadi,

Hussain Alrand,

Habiba Alsafar,

Asma Fikri

Publication year - 2022

Publication title -

journal of travel medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.985

H-Index - 59

eISSN - 1708-8305

pISSN - 1195-1982

DOI - 10.1093/jtm/taac036

Subject(s) - medicine , covid-19 , outbreak , booster (rocketry) , booster dose , virology , vaccination , confidence interval , pediatrics , infectious disease (medical specialty) , disease , virus , titer , physics , astronomy

Inactivated vaccine BBIBP-CorV {Sinopharm; 95% [95% confidence interval (CI): 94, 97%]} and the mRNA vaccine BNT162b2 [Pfizer-BioNTech; 98% (95% CI: 86, 99%)] demonstrated protection against COVID-19 related hospitalizations from the Delta (B.1.617.2) variant. Ongoing efforts are necessary to target vaccine hesitancy and to promote booster shots for protection against severe COVID-19 disease and arising variants of concern.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research